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Purpose: Previous studies have described γ-synuclein as a protein highly expressed in retinal ganglion cells (RGCs), and
a loss of RGCs correlates with a downregulation of γ-synuclein gene expression in glaucoma. Here we asked whether γ-
synuclein expression in the retina can be considered a specific marker of RGCs.
Methods:  γ-Synuclein  expression  was  examined  with  immunohistochemistry  in  retinal  sections  from  normal  and
glaucomatous human eyes. Primary cultures of RGCs from Sprague-Dawley rats purified by sequential immunopanning
using a monoclonal antibody to Thy1–1, cultures of A7 immortalized optic nerve astrocytes from newborn rats, and the
immortalized RGC-5 cell line were studied using immunofluorescence and quantitative RT–PCR.
Results: γ-Synuclein was highly expressed in RGCs in the human retina and was localized in cytoplasm adjacent to the
RGC nuclear marker, Brn-3a. Axons of RGCs were immunopositive for γ-synuclein in the nerve fiber layer (NFL), the
lamina cribrosa and the retrobulbar optic nerve. In the optic nerve of glaucoma patients, axon swellings were likewise
immunopositive, whereas in the retina of patients with retinoblastoma, NFL staining appeared reduced. In primary rat
RGCs and in immortalized RGC-5 cultures, γ-synuclein was localized predominantly in the perinuclear area and in cell
processes. Among rat retinal cells in culture, all Brn-3a positive cells were stained with a γ-synuclein antibody; rare γ-
synuclein-positive cells were not stained by the Brn-3a antibody.
Conclusions: γ-Synuclein is selectively and abundantly expressed in human RGCs in vivo, primary rat RGCs in vitro,
and immortalized RGC-5 cells. In pathology, γ-synuclein abundance may vary between RGC somas and axons. Coincident
Brn-3a and γ-synuclein expression suggests that strong γ-synuclein expression can be considered a marker of RGCs.
Future translational approaches might include using a γ-synuclein promoter for the specific delivery of siRNA or
therapeutic proteins to RGCs.
Glaucoma results in a slow, progressive, and selective
dysfunction and ultimately apoptotic death of retinal ganglion
cells (RGCs), the retinal neurons that project to the brain via
the optic nerve [1-6]. The precise mechanisms involved in
glaucomatous RGC death are not completely understood, but
it is widely accepted that pathophysiological events in the
retinal ganglion cell layer (GCL) and at the optic nerve head,
through which RGC axons pass, play a prominent role in the
development  of  this  neuropathy.  Therefore,  a  better
appreciation of the factors involved in ganglion cell death is
central  to  the  development  of  therapeutic  strategies  [1,2].
RGCs  make  up  only  approximately  45%  of  RGC  layer
neurons  in  the  mouse  [7].  RGCs  can  not  be  reliably
distinguished from the other neurons in the GCL, such as
displaced amacrine cells, based on cell morphology alone
[7,8].  In  addition,  RGCs  are  structurally  and  functionally
heterogeneous,  and  information  regarding  the  molecular
composition and characteristics of RGC subtypes remains
incomplete. Further progress in this field is difficult because
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of  the  paucity  of  markers  distinguishing  RGCs  and  their
subtypes.
Finding and characterizing markers for RGC death could
be  an  important  step  in  understanding  the  molecular  and
cellular  processes  in  glaucoma.  Thy1–1  and  Brn-3  are
currently used as markers of RGCs, but Thy1–1 is not a good
marker of RGC loss in models of retinal damage [9], and
Brn-3c is only expressed in 50% of RGCs [10-12].
Here we show that γ-synuclein is highly and specifically
expressed in RGCs in the intact retina, in primary cultures of
RGCs, and in an immortalized cell line, RGC-5. We further
demonstrate  that  γ-synuclein  localization  changes  in  the
glaucomatous retina, and may thus be used as a marker for
damaged RGCs in glaucoma.
METHODS
Retina  and  optic  nerve:  tissue  section  preparation  and
staining: Human eyes, from donors aged 53–70 years who had
no history of eye disease, were obtained from Mid-America
Transplant Services (St. Louis, MO). Time from death to
preservation was 4–8 h.
Retinas from two different one-year-old patients’ eyes,
each enucleated for retinoblastoma, were compared with the
retina of a control individual of the same age that died as a
result of an accident. Paraffin-embedded blocks were received
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1540from Dr. Morton Smith (Department of Pathology, University
of Wisconsin, Madison, WI). The preparation of samples was
conducted in accordance with the tenets of the Declaration of
Helsinki and approved by the Institutional Review Board of
the University of Wisconsin. Samples of optic nerve were
received  from  Dr.  Martin  B.  Wax  (Research  and
Development, Alcon Research Ltd, Fort Worth, TX). The
donating patients were 61–72 years old at the time of death
and had primary open-angle glaucoma. Clinical findings of
these patients were documented for a follow-up period of five
to eight years. Neither these donors nor the control 70-year-
old  individual  were  reported  to  have  diabetes,  collagen
vascular disease, or sepsis. The cause of death for these donors
was acute myocardial infarction or cardiopulmonary failure.
Other characteristics of these patients are described in [13].
The eyes were enucleated within 4 h after death and processed
and fixed within 6 h in either 10% buffered formaldehyde or
4% paraformaldehyde. The posterior poles were dissected free
of surrounding tissues, washed extensively in 0.2% glycine in
phosphate-buffered  saline  (PBS;  0.8%  NaCl,  0.02%  KCl,
0.144% Na2HPO4, 0.024% KH2PO4, pH 7.4) and embedded
in paraffin. The sections were prepared as described earlier
[13].
Immunofluorescent  staining:  Human  retinas  from  donors
without eye diseases were stained with a 1:1000 dilution of
monoclonal γ-synuclein antibody (clone 1H10D2; Antagene,
Mountain View, CA) and 1:2000 antirabbit polyclonal Brn-3a
antibody (gift of Dr. Eric E. Turner, University of California
San Diego, La Jolla, CA), followed by a 1:1000 dilution of
fluorescent  secondary  antibodies  antirabbit-Alexa-568  and
antimouse-Alexa-488 (Invitrogen, Carlsbad, CA).
Immunohistochemical  staining  of  retinas  from
retinoblastoma patients: After enucleation, eyes were washed
in PBS containing 0.1% glycine and processed for paraffin
embedding. Next, 8–10 5 µm slices were cut and applied to
silane-coated  slides  (Fisher  brand  Super  frost  Plus  slides
catalog  number  12–550–15;  Fisher  Scientific,  Pittsburgh,
PA).  Before  immunostaining,  the  sections  were
deparaffinized and incubated for 1 h in PBS-glycine (0.01%
glycine in PBS, pH 7.4; Sigma-Aldrich, St. Louis, MO) at
room temperature to reduce nonspecific binding. Slides were
further preincubated with 5% milk for 30 min, and then rinsed
and  incubated  with  primary  antibodies  (1:100)  against  γ-
synuclein  (Abcam,  Cambridge,  MA)  for  30  min.  A
biotinylated rabbit secondary antibody (Vectastain Elite ABC
kit; Vector Laboratories, Burlingame, CA) was placed on the
sections and incubated for 30 min, washed off with PBS, and
exposed  to  streptavidin-peroxidase  conjugate  (Vector
Laboratories)  for  30  min.  The  bound  antibody-peroxidase
complexes  on  the  sections  were  visualized  using  a  3,  3-
diaminobenzidine  tetrahydrochloride  (DAB)  substrate
solution consisting of 1.5 mg DAB and 50 μl of 30% hydrogen
peroxide in 10 ml of 0.1 M Tris-HCl, pH 7.6. The sections
were incubated in the dark until brown staining appeared,
washed in PBS, counterstained with hematoxylin, dehydrated,
and coverslipped with Permount. Control sections were run in
parallel, omitting only the primary antibody.
Preparation  of  rat  retinal  cells:  After  dissection  from
postnatal  day  0  Sprague-Dawley  rats  (Charles  River
Laboratories, Wilmington, MA), retinas were digested with
papain (165u/10 ml; Worthington Biochemical, Lakewood,
NJ) for 30 min and then triturated mechanically until all the
cells were in suspension. The cells were seeded on coverslips
precoated  with  poly-D-lysine  and  laminin  at  a  density  of
50,000 cells per coverslip. The cells were incubated overnight
at  37  °C  with  10%  CO2  in  serum-free  Neurobasal  media
(Invitrogen)  containing  5  µg/ml  insulin,  50  µg/ml  brain-
derived  neurotrophic  factor  (BDNF),  10  µg/ml  ciliary
neurotrophic factor (CNTF), and 10 µg/ml forskolin.
Primary  cultures  of  retinal  ganglion  cells:  For  primary
cultures of RGCs from Sprague-Dawley rats, the cells were
purified  by  sequential  immunopanning  to  a  99.5%  purity
[14] using a monoclonal antibody to Thy1–1 as described
[14-17].
Briefly, whole retina tissue was removed from rats from
four litters, incubated in a papain solution as described above,
dissociated into single-cell suspension, and incubated with
1:100 antimacrophage antiserum (Axell Accurate Chemical
and  Scientific  Corp,  Westbury,  NY).  The  retinal  cell
suspension was passed over panning plates coated with goat
anti-rabbit secondary antibodies to remove macrophages and
endothelial cells. The remaining, unbound cells were then
placed  on  panning  plates  containing  Thy1–1  antibody
(T11D7) to bind RGCs, and unbound cells were rinsed away.
RGCs were released after incubation with a trypsin solution.
RGCs  were  cultured  overnight  on  poly-D-lysine  (Sigma-
Aldrich) and 2 mg/ml laminin (Telios/Invitrogen, Carlsbad,
CA)  in  serum-free  defined  medium  containing  50  ng/ml
BDNF, 10 ng/ml CNTF, 5 µg/ml insulin, and 5 µM forskolin
as described [14,16]. These cultures typically generate a yield
of RGCs between 50% and 70%, with a survival of more than
80% over the first day in culture [14].
A7  astrocytes  from  rat  optic  nerve:  The  culture  of
immortalized optic nerve astrocytes from newborn rats was a
generous gift of Dr. Herbert Geller (NHLBI, NIH, Bethesda,
MD). The cells were grown as described previously [18] in
DMEM with 2 mM glutamine, 10% FBS, 0.45% glucose in
the presence of penicillin/streptomycin (final concentration of
penicillin  100  IU/ml,  streptomycin  100  μg/ml).  The  cells
expressed an astrocyte-specific marker, glial fibrillary acidic
protein (GFAP).
Culture of the rat retinal ganglion cell line, RGC-5: RGC-5
cells  [19]  were  kindly  provided  by  Dr.  Raghu
Krishnamoorthy, Department of Cell Biology and Genetics,
University of North Texas Health Science Center, Fort Worth,
TX.  The  cells  were  maintained  in  Dulbecco’s  modified
Eagle’s medium containing 10% fetal bovine serum (BRL,
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1541Gaithersburg,  MD),  100  U/ml  penicillin,  and  100  µg/ml
streptomycin (Sigma-Aldrich). The cells were grown in a
humidified atmosphere of 95% air and 5% CO2 at 37 °C. The
RGC-5 cells have a doubling time of approximately 18–20 h
and  were  passaged  by  trypsinization  every  3–4  days  as
previously described [20].
Immunofluorescent  staining  of  RGC-5  cells:
Immunofluorescent staining of an immortalized cell culture
(RGC-5) was done as described previously [21] with slight
modifications. Briefly, cells were split on glass coverslips
treated with 0.02% poly-D-lysine. Before staining, the cells
were washed with PBS, fixed with 100% methanol for 10 min
at –20 °C, and then fixed with a 1:1 methanol: acetone mixture
for 4 min at −20 °C. After washing by PBS (4 times, 10 min
each washing), the coverslips were treated with 5% BSA in
PBS-T (PBS + 0.3% Triton X-100) for blocking unspecific
binding  (1  h,  room  temperature).  The  coverslips  were
incubated overnight at 4 °C with a 1:150 dilution γ-synuclein
polyclonal  antibody  (Abcam,  Cambridge,  MA).  After
washing, the coverslips were incubated with a 1:300 dilution
of  secondary  antirabbit  antibodies  to  which  Cy2  was
conjugated (Jackson Laboratories, Bar Harbor, ME). After
another washing, the coverslips were loaded on mounting
solution  containing  DAPI  (Invitrogen),  and  fluorescent
images  were  recorded  with  a  Leica  DMI  6000B  inverted
microscope.
Figure 1. γ-Synuclein and Brn-3a localization were examined in the
human retina by immunofluorescence. γ-Synuclein (red) was present
in the cytoplasm of retinal ganglion cells (RGCs; triangles) and in
the nerve fiber layer (NFL), while Brn-3a (green, arrowheads) was
observed in RGC nuclei. Arrows mark cells in the retinal ganglion
cell  layer  (GCL)  that  were  not  stained  by  either  Brn-3a  or  γ-
synuclein. Nuclei throughout the retina are counterstained with DAPI
(blue), and little immunofluorescence is noted through the inner or
outer plexiform layers (IPL and OPL, respectively), or inner and
outer nuclear layers (INL and ONL, respectively). Thus γ-synuclein
is localized both in the body of RGC and in their axons.
Immunostaining  of  retinal  cell  suspension  and  primary
cultures  of  retinal  ganglion  cells:  Following  overnight
incubation,  the  staining  of  the  rat  primary  culture  was
conducted as described in the section above for RGC-5 cells
but with slight modifications. The coverslips were incubated
with a 1:100 dilution of the γ-synuclein polyclonal rabbit
antibody (Abcam) and a 1:100 dilution of a mouse monoclonal
Brn-3a  antibody  (MAB1585;  Chemicon,  Temecula,  CA)
overnight at 4 °C. The next day the coverslips were washed
with PBS (three times, 15 min each wash) on a shaker at room
temperature and incubated with secondary antibodies for 90
min. As a secondary antibody we used highly cross adsorbed
AlexaFluor488 goat antirabbit IgG (H+L) and AlexaFluor568
donkey  antimouse  IgG  (Invitrogen).  After  washing,  the
coverslips were mounted in Vectashield with DAPI (Vector
Laboratories Inc., Burlingame, CA), and fluorescent images
were  obtained  with  a  fluorescence  microscope  (Axiovert
200M, Carl Zeiss, Germany).
RNA isolation: RNA was isolated from 4x106 cultured RGC-5
cells using the spin column method of an RNeasy Protect Mini
Kit  (Qiagen,  Valencia,  CA),  and  the  RNA  was  stored  at
−80  °C.  The  isolated  RNA  was  quantified  by
spectrophotometric absorbance assuming that 1 absorbance
unit at 260 nm in 10 mM Tris-HCl, pH 7.5 corresponds to an
RNA concentration of 44 µg/ml. Only samples with an A260/
A280 ratio higher than 1.9 were used. The integrity of RNA was
checked by denaturing 1.2% agarose gel electrophoresis in the
presence of formaldehyde. rRNAs appeared as sharp bands,
and the ratio of 28S rRNA to 18S rRNA quantified under UV
light with Kodak Image Station 440CF (Eastman Kodak Co.,
Rochester, NY) was 2:1. The RNA was converted into cDNA
using the High-Capacity cDNA Reverse Transcription Kit
with random primers (Applied Biosystems, Foster City, CA).
qRT–PCR: Relative quantification was conducted in a two
step qRT–PCR protocol using TaqMan starter kit reagents,
Quantitative  Real-Time  PCR  kits,  and  a  7300  series
instrument from the manufacturer (Applied Biosystems). The
following  probes  specific  for  rat  mRNAs  were  used:  Rn
00569821-m1  for  α-synuclein,  Rn00589963-m1  for  β-
synuclein,  Rn00581652-m1  for  γ-synuclein,  and
Rn00667869-m1  for  β-actin.  The  latter  was  used  as  an
endogenous  control.  Reverse  transcription  was  carried  by
incubating  the  RNA  samples  with  50  U/μl  of  reverse
transcriptase (RT; 10 min, 25 °C, 120 min, 37 °C) using High
Capacity  cDNA  Reverse  Transcription  kit  (Applied
Biosystems)  and  following  recommendations  of  the
manufacturer. A minus RT control containing all the reaction
components except the reverse transcriptase was included in
all  qRT–PCR  experiments  to  test  genomic  DNA
contamination. Amplification was performed using TaqMan
Universal PCR master mix (Applied Biosystems) and the
following conditions: 2 min at 50 °C (hold), 10 min at 95 °C
(hold); 15 s at 95 °C, 45 cycles; 1 min 60 °C (hold). The
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1542samples were amplified in duplicate, and three independent
isolations  of  RNA/cDNA  were  used.  Control  samples  in
which cDNA was not added did not give any amplification
signals.  Amplification  products  were  confirmed  by
sequencing.
Enzyme  linked  immunoassay  of  synuclein:  Wells  in  each
ELISA  plate  were  coated  with  1  µg/ml  of  γ-synuclein
antibody E-20, sc-10698 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) in 50 µl of 50 mM sodium carbonate, pH 9.6
(coating solution) by an overnight incubation at 4 °C. The next
morning the wells in the plate were washed three times with
a 0.1% solution of PBS-Tween-20 and incubated with 200 µl/
well of blocking solution (Super Block Blocking buffer in
PBS; Pierce, Rockford, IL) for 30 min at 37 °C. Next, the plate
was  washed  again  with  the  PBS-Tween  buffer.  For  the
calibration  curve,  recombinant  γ-synuclein  [22]  was  used
from 2.0 to 2000 pg/ml. In addition, a set of ten-fold dilutions
of  the  RGC-5  or  A7  cell  extracts  were  added  in  the
neighboring wells and incubated for 2–3 h at 37 °C. The wells
were washed with PBS-Tween, then a secondary antibody,
syn15–S (Alpha-Diagnostic, San Antonio, TX), was added at
a 1:5,000 dilution and incubated for 1 h at 37 °C. The washing
procedure with PBS-Tween was repeated, and an incubation
with  1:5,000  antirabbit-HRP  (Invitrogen)  as  a  developing
antibody solution was performed for 30 min at 37 °C. After
washing,  100  µl/well  of  3,  3′,  5,  5′  tetramethylbenzidine
(TMB) substrate was added (ImmunoPure TMB substrate,
Pierce, Rockford, IL). When blue color devoloped, 100 µl/
well of 2N H2SO4 was added to stop the reaction, and the
absorbance was measured at 450 nm.
RESULTS
We previously found that γ-synuclein is expressed in RGCs
[23]. Here we explored whether γ-synuclein expression is
RGC-specific. In sections of the human retina (Figure 1), γ-
synuclein antibody stained the cytoplasm and processes of
cells in the ganglion cell layer (GCL) that were positive for
the  RGC  marker  Brn-3a.  All  Brn-3a-positive  nuclei  were
surrounded  by  γ-synuclein-positive  cytoplasm.  Cells  not
stained  by  either  of  these  two  markers  (Figure  1)  may
represent  displaced  amacrine  cells  normally  found  in  the
GCL.  Thus  γ-synuclein  appeared  to  demonstrate  RGC-
specific expression in human retina. The presence of a weak,
punctate signal in the inner plexiform layer (IPL) in these
retinal sections (Figure 1) may be explained by slight cross-
reaction of γ-synuclein antibody with α-synuclein, which is
localized in the IPL [23]. Thus in human retinal sections, γ-
synuclein colocalizes with Brn-3a-positive RGCs.
We  next  considered  whether  γ-synuclein  expression
changed  in  retinal  disease.  In  the  retinas  of  patients  with
retinoblastoma, γ-synuclein immunoreactivity was reduced in
the nerve fiber layer (NFL), but increased in the cell bodies of
RGCs in the GCL (Figure 2). In a second retinoblastoma
patient, we observed similar changes in the pattern of staining
(data not shown). In three glaucoma patients, swollen axons
Figure 2. Localization of γ-synuclein was studied by immunohistochemistry in a normal human retina (A) and in the retina of an age-matched
patient with retinoblastoma (B). γ-Synuclein was detected using a diaminobenzidine reagent (brown, peroxidase). Tissues were counterstained
with hematoxylin (blue). Sections were stained with an antibody that recognized γ-synuclein, but not the other members of the synuclein
family. The retina of the retinoblastoma patient (B) demonstrated more intense γ-synuclein immunoreactivity in retinal ganglion cell bodies
(arrows) and less intensive staining in the nerve fiber layer (NFL) compared with the normal retina (A).
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1543and  axonal  fragments  were  also  immunopositive  for  γ-
synuclein (in Figure 3 a representative sample is shown).
In the optic nerve of a patient with glaucoma, RGC axons
were immunopositive for γ-synuclein, and swollen axons and
axonal fragments were also immunopositive for γ-synuclein
(Figure 3). Thus in example eyes with either retinoblastoma
or glaucoma, γ-synuclein changed its pattern of subcellular
expression, but appeared to maintain RGC expression and
specificity.
We next analyzed the expression and localization of γ-
synuclein  in  an  immortalized  RGC  cell  line,  RGC-5.  In
RGC-5, γ-synuclein demonstrated a diffuse localization in the
cytoplasm  and  in  cell  processes,  with  a  typical  punctate
staining predominantly in the perinuclear area (Figure 4A-B).
The nuclei of all these cells were stained with a polyclonal
antibody against Brn-3a (not shown).
By  quantitative  RT–PCR,  we  analyzed  γ-synuclein
mRNA  expression  in  RGC-5  cells.  γ-Synuclein  mRNA
expression  was  more  abundant  compared  to  α-  and  β-
synuclein levels with β-actin as an endogenous control (Figure
4C) . The threshold cycle (CT) was found to be 24.4±0.3 for
γ-synuclein, 26.7±0.4 for α-synuclein and 36.9±0.4 for β-
synuclein. Because γ-synuclein is localized in the optic nerve
[13], we also considered the possibility that it is expressed by
astrocytes. Although we did not generate primary cultures of
optic nerve astrocytes, we were able to obtain the A7 astrocyte
cell line. Using ELISA analysis, extracts of RGC-5 cells had
significantly higher expression of γ-synuclein protein than A7
astrocyte cells (3.3 versus 0.8 µg/mg of total protein, p<0.01).
We next used cultures of rat retinal cells and rat RGCs
purified by immunopanning to consider whether γ-synuclein
was specific for RGCs. In primary cultures of purified rat
RGCs,  γ-synuclein  was  again  localized  in  the  cytoplasm,
while Brn-3a was expressed in the nuclei (Figure 5). The
asymmetry of the staining was mainly from the asymmetry of
the  cytoplasm.  When  retinal  suspensions  were
immunostained with antibodies to γ-synuclein and Brn-3a, we
identified four types of cells (Figure 6). Most abundant were
cells not stained by either γ-synuclein or Brn-3a antibodies,
as expected since RGCs make up a small fraction of the
neurons in the retina. About 1% of retinal cells were marked
by intense staining by both antibodies. Finally, there were
retinal cells weakly double-positive, and rare γ-synuclein-
positive/Brn3a-negative  cells  (Figure  6).  We  did  not
determine  whether  this  last  group  represented  a  Brn-3a-
Figure 3. Immunohistochemical staining with a γ-synuclein antibody was used to examine a non-glaucomatous human optic nerve in the area
immediately posterior to the lamina cribrosa (A) and the retrobulbar optic nerve from a patient with primary open-angle glaucoma (B). In
both sections, γ-synuclein reactivity can be seen along presumptive retinal ganglion cell axon bundles. In section B, arrows show swollen
axons and axons fragment immunopositive for γ-synuclein. These results confirm the presence of γ-synuclein in axons of RGC and its
immunopathology in glaucoma.
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1544negative subtype of RGC, or a different retinal cell type. We
noted  at  higher  magnification  that  Brn-3a-positive  and
Brn-3a-negative  cells  differed  in  their  γ-synuclein
immunoreactivity  (Figure  7).  Brn-3a  positive  cells  were
extensively  stained  throughout  the  cytoplasm  by  the  γ-
synuclein antibody, and more strongly in the perinuclear area
where we observed bright, punctate reactivity. In contrast,
Brn-3a  negative  cells  demonstrated  only  a  weak  dot-like
staining in a small part of the cell. In all cases, Brn-3a staining
overlapped  with  DAPI  nuclear  staining  (Figure  7).  Thus,
taken  together,  these  data  demonstrate  that  brighter  and
broader cytoplasmic staining of γ-synuclein overlapped well
with Brn-3a staining, and that γ-synuclein appears to be an
RGC-specific marker.
DISCUSSION
Here we show that γ-synuclein is a specific marker of RGCs,
and that its expression and localization are altered in ocular
diseases.  We  have  demonstrated  similar  results  with  two
Figure 5. Localization of γ-synuclein and Brn-3a were examined in
a primary culture of rat retinal ganglion cells (RGCs). A: DAPI (blue)
counterstained the nuclei. B: Brn-3a (green) was localized to RGC
nuclei. C: γ-synuclein (red) was localized throughout the cytoplasm
(arrowheads) and processes. A merged image of A, B, and C is shown
in D. Thus, in primary culture of RGCs, γ-synuclein is localized in
the cytoplasm and processes, while Brn-3a in the nuclei.
Figure  4.  Retinal  ganglion  cell-5
(RGC-5)  cell-line  expression  of  γ-
synuclein  protein  and  mRNA  were
investigated using immunofluorescence
and  quantitative  RT–PCR.  A:
Immunofluorescent staining of RGC-5
cultures  reveals  γ-synuclein  staining
(green) localized in the perinuclear area
(arrowheads)  and  in  cell  processes
(arrows).  B:  no  fluorescence  was
detected  in  the  absence  of  primary
antibody.  Nuclei  were  counterstained
with  DAPI  (blue).  C:  qRT–PCR  of
endogenous  synuclein-family
transcripts in RGC-5 demonstrates that
γ-Synuclein  had  the  highest  level  of
expression (Ct=24.44±0.3), followed by
α-synuclein (Ct=26.72±0.3) and finally
β-synuclein  (Ct=36.93±0.4).  Ct
represents  threshold  cycles;  a  lower
number reflects higher levels of initial
mRNA.  A  representative  duplicate
curves are shown for three independent
isolation.  Ct  differences  were
statistically significant (p<0.05).
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1545different γ-synuclein antibodies in this study, and a third in a
previous study [23], and have found similar patterns of RGC
specificity in human and rodent retinas. The identification of
specific molecular markers for RGCs, which may have more
than  a  dozen  subtypes  [7,24,25],  has  been  difficult.
Previously,  Thy1–1  and  Brn-3  family  proteins  have  been
described  as  RGC  markers  [9-12,26].  However,  their
expression is developmentally regulated and Thy1 expression
is not limited to RGCs, but is also weakly expressed by a
subset  of  cells  in  the  inner  nuclear  layer.  In  contrast,  γ-
synuclein mRNA and protein are expressed in neurons from
the earliest stages of axonal outgrowth and are maintained at
a high level throughout life [27]. γ-Synuclein and other such
markers may be useful to investigate normal functions of
RGCs and the mechanisms underlying their death [16,28].
Synucleins  are  small  natively  unfolded  proteins
implicated in neurodegenerative diseases and some forms of
cancer [27,29-31]. We and others previously found that three
members  of  the  synuclein  family  were  differentially
expressed  in  the  retina  [23,32].  α-  and  β-Synucleins  are
expressed mainly in the inner plexiform layer (IPL), inner
nuclear layer, and in photoreceptor cells, whereas here we find
that γ-synuclein is expressed by RGCs in the ganglion cell
layer and in their axons in the nerve fiber layer (NFL). Here
we found that, in the retinas of retinoblastoma patients, γ-
Figure  6.  γ-Synuclein  specificity  was  examined  using
immunofluorescent  staining  of  rat  retinal  cells.  A:  DAPI  (blue)
counterstained the nuclei. B: Brn-3a (green) was localized to RGC
nuclei. C: γ-synuclein (red) was localized throughout the cytoplasm
(arrowheads) and processes (arrows). A merged image of A, B, and
C is shown in D. Many cells demonstrated neither Brn-3a nor γ-
synuclein  reactivity  (horizontal  arrows  in  A).  A  subset  of
presumptive retinal ganglion cells demonstrated intensive staining
by both γ-synuclein and Brn-3a (full arrowheads in B, C, and D),
while  many  other  cells  showed  only  weak  staining  by  both  γ-
synuclein and Brn-3a (arrowheads in B and C). A few cells were
stained by γ-synuclein, but not by Brn-3a (vertical arrows in B).
synuclein expression was reduced in the NFL and increased
in the cell bodies of subsets of RGCs. In patients with primary
open-angle  glaucoma,  the  bundles  of  axons  and  axon
swellings remained immunopositive for γ-synuclein. The role
of  this  protein  in  retinal  cancers  and  retinal  degenerative
diseases remains to be studied, but these data suggest that γ-
synuclein’s role in other disease processes [30,31] may be
mirrored in the eye. For example, synucleins bind to vesicles
through their N-terminal repeat region and are involved in
axonal  transport  [33].  The  accumulation  of  γ-synuclein
aggregates we observed in a glaucomatous optic nerve might
be a result of the disruption of γ-synuclein transport in axons
of  RGCs,  consistent  with  the  decrease  in  γ-synuclein
expression and the axonal transport impairment in the DBA/
2J mouse model of glaucoma [34]. γ-Synuclein could also
play a causative role in axonal transport deficits through its
ability to modulate neurofilament network integrity [29] or
through its ability to upregulate matrix metalloproteinase 9,
an enzyme modulating extracellular matrix [22] that plays a
role in retinal ganglion cell death in animal models [35.
In this study our antibodies did not distinguish expression
of differentially modified γ-synuclein proteins in RGCs and
RGC axons. In a previous study, it was demonstrated that all
Figure 7. γ-Synuclein subcellular localization was examined using
immunofluorescent  staining  of  rat  retinal  cells.  A:  DAPI  (blue)
counterstained the nuclei. B: Brn-3a (red) was localized to RGC
nuclei.  C:  γ-synuclein  (green)  was  co-expressed  by  the  Brn-3a
expressing cell (arrows) but only weakly by a non-Brn-3a-expressing
cell (arrowhead). A merged image of A, B, and C is shown in D.
Immunofluorescent staining of retinal cell suspension. A: DAPI, B:
Brn-3a, C: γ-synuclein, D: merged images. Horizontal arrows show
a cell immunopositive for both Brn-3a and γ-synuclein. Arrowhead
(C and D) points to a cell not stained by Brn-3a antibody that is
stained by a γ-synuclein antibody. Vertical arrow (C and D) points
to  the  localization  of  γ-synuclein  in  the  perinuclear  area.  Thus,
brighter and broader cytoplasmic staining of γ-synuclein overlapped
well with Brn-3a staining.
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1546three synucleins are substrates of G-protein coupled receptor
kinases [36] which phosphorylate Ser-129 in α-synuclein and
the  corresponding  Ser-124  in  γ-synuclein.  Other
posttranslational  modifications  have  been  described  for
synucleins, including sumoylation, O-glycosylation, tyrosine
nitrosylation among others [37,38]. It would be interesting to
determine  whether  γ-synuclein  is  differentially  modified
during development or in disease.
Taken together, these data demonstrate that γ-synuclein
is  highly  expressed  in  RGCs,  and  that  this  high  level  of
expression is largely RGC-specific. The use of a γ-synuclein
promoter [39] for specific delivery of siRNA or fluorescent
markers  to  RGCs  might  be  useful  for  future  translational
approaches. We propose that this marker may become an
important  tool  for  the  future  investigation  of  normal
physiology of RGCs and the mechanisms underlying their
death, and is itself a strong candidate for playing a role in the
pathophysiology  of  RGC  death  in  glaucoma  and  other
degenerative diseases.
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